Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Nirmatrelvir Resistance in an Immunocompromised Patient with Persistent Coronavirus Disease 2019.

Viruses - 30 Apr 2024

Yamamoto Chie, Taniguchi Masashi, Furukawa Keitaro, Inaba Toru, Niiyama Yui, Ide Daisuke, Mizutani Shinsuke, Kuroda Junya, Tanino Yoko, Nishioka Keisuke, Watanabe Yohei, Takayama Koichi, Nakaya Takaaki, Nukui Yoko

Abstract excerpt

Although the coronavirus disease 2019 (COVID-19) pandemic is coming to an end, it still poses a threat to the immunocompromised and others with underlying diseases. Especially in cases of persistent COVID-19, new mutations conferring resistance to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) therapies have considerable clinical implications. We present a patient who independently acquired a T21I...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alanine
Share to Coronavirus 3C Proteases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to COVID-19

Share to COVID-19 Drug Treatment

Share to Drug Resistance, Viral

Share to Immunocompromised Host

Share to Multiple Myeloma

Share to SARS-CoV-2

Source

Open in PubMed Open full text

Identifiers

PMID: 38793600
DOI: 10.3390/v16050718
PMCID: PMC11125932

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Nirmatrelvir Resistance in an Immunocompromised Patient with Persistent Coronavirus Disease 2019.PMID 38793600Read ↗

Emergence of transmissible SARS-CoV-2 variants with decreased sensitivity to antivirals in immunocompromised patients with persistent infections.Semantic proximity Read ↗

Emergence of transmissible SARS-CoV-2 variants with decreased sensitivity to antivirals in immunocompromised patients with persistent infectionsSemantic proximity Read ↗

Emerging SARS-CoV-2 Resistance After Antiviral Treatment.Semantic proximity Read ↗

Characterization of remdesivir resistance mutations in COVID-19 patients with various immunosuppressive diseases.Semantic proximity Read ↗

Viral Load Rebound in Placebo and Nirmatrelvir-Ritonavir Treated COVID-19 Patients is not Associated with Recurrence of Severe Disease or MutationsSemantic proximity Read ↗

Nirmatrelvir Resistant SARS-CoV-2 Variants with High Fitness in VitroSemantic proximity Read ↗

Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture systemSemantic proximity Read ↗

The effect of molnupiravir and nirmatrelvir on SARS-CoV-2 genome diversity in severe models of COVID-19Semantic proximity Read ↗

Nirmatrelvir Resistance-de Novo E166V/L50V Mutations in an Immunocompromised Patient Treated With Prolonged Nirmatrelvir/Ritonavir Monotherapy Leading to Clinical and Virological Treatment Failure-a Case Report.Semantic proximity Read ↗

Remdesivir-Nirmatrelvir Combination: In Vitro Activity and a Case ReportSemantic proximity Read ↗

Emergence of SARS-CoV-2 with Dual-Drug Resistant Mutations During a Long-Term Infection in a Kidney Transplant RecipientSemantic proximity Read ↗

Characterization of Virologic Rebound Following Nirmatrelvir-Ritonavir Treatment for Coronavirus Disease 2019 (COVID-19).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.